{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:21:44Z","timestamp":1782926504949,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82374360, 81903974)"],"award-info":[{"award-number":["82374360, 81903974)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04600-2","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:46:41Z","timestamp":1762940801000},"page":"5829-5841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and serum metabolomic analysis of Jiu Wei Qingzhi Formula in treating non-alcoholic fatty liver disease: study protocol for a parallel-armed, randomized controlled trial"],"prefix":"10.1007","volume":"399","author":[{"given":"Huilian","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanyuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"1 Suppl","key":"4600_CR1","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1 Suppl):S47-64","journal-title":"J Hepatol"},{"issue":"6","key":"4600_CR2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00125-016-3910-y","volume":"59","author":"CD Byrne","year":"2016","unstructured":"Byrne CD, Targher G (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia 59(6):1141\u20131144","journal-title":"Diabetologia"},{"key":"4600_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/bs.ircmb.2015.10.001","volume":"321","author":"E Calzada","year":"2016","unstructured":"Calzada E, Onguka O, Claypool SM (2016) Phosphatidylethanolamine metabolism in health and disease. Int Rev Cell Mol Biol 321:29\u201388","journal-title":"Int Rev Cell Mol Biol"},{"issue":"3","key":"4600_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","volume":"35","author":"NWS Chew","year":"2023","unstructured":"Chew NWS, Ng CH, Tan DJH et al (2023) The global burden of metabolic disease: data from 2000 to 2019. Cell Metab 35(3):414-428.e3","journal-title":"Cell Metab"},{"issue":"2","key":"4600_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP et al (2023) Global burden of liver disease: 2023 update. J Hepatol 79(2):516\u2013537","journal-title":"J Hepatol"},{"issue":"21","key":"4600_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111905","volume":"22","author":"S Di Mauro","year":"2021","unstructured":"Di Mauro S, Scamporrino A, Filippello A et al (2021) Clinical and molecular biomarkers for diagnosis and staging of NAFLD. Int J Mol Sci 22(21):11905","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4600_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","volume":"13","author":"A Duseja","year":"2023","unstructured":"Duseja A, Singh SP, De A et al (2023) Indian National Association for Study of the Liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD). J Clin Exp Hepatol 13(2):273\u2013302","journal-title":"J Clin Exp Hepatol"},{"issue":"15","key":"4600_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28155637","volume":"28","author":"C Eurtivong","year":"2023","unstructured":"Eurtivong C, Leung E, Sharma N, Reynisson J et al (2023) Phosphatidylcholine-specific phospholipase c as a promising drug target. Molecules 28(15):5637","journal-title":"Molecules"},{"issue":"22","key":"4600_CR9","doi-asserted-by":"publisher","first-page":"11705","DOI":"10.1039\/D2FO02349K","volume":"13","author":"ZK Fan","year":"2022","unstructured":"Fan ZK, Ma WJ, Zhang W et al (2022) Elevated serum phosphatidylcholine (16:1\/22:6) levels promoted by fish oil and vitamin D3 are highly correlated with biomarkers of non-alcoholic fatty liver disease in Chinese subjects. Food Funct 13(22):11705\u201311714","journal-title":"Food Funct"},{"issue":"D1","key":"4600_CR10","doi-asserted-by":"publisher","first-page":"D1197","DOI":"10.1093\/nar\/gkaa1063","volume":"49","author":"S Fang","year":"2021","unstructured":"Fang S, Dong L, Liu L et al (2021) HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res 49(D1):D1197\u2013D1206","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"4600_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/09687688.2015.1066894","volume":"32","author":"S Furse","year":"2015","unstructured":"Furse S, de Kroon AI (2015) Phosphatidylcholine\u2019s functions beyond that of a membrane brick. Mol Membr Biol 32(4):117\u2013119","journal-title":"Mol Membr Biol"},{"key":"4600_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","volume":"688","author":"CR Gault","year":"2010","unstructured":"Gault CR, Obeid LM, Hannun YA (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688:1\u201323","journal-title":"Adv Exp Med Biol"},{"key":"4600_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep03267","volume":"3","author":"N Goto-Inoue","year":"2013","unstructured":"Goto-Inoue N, Yamada K, Inagaki A et al (2013) Lipidomics analysis revealed the phospholipid compositional changes in muscle by chronic exercise and high-fat diet. Sci Rep 3:3267","journal-title":"Sci Rep"},{"issue":"24","key":"4600_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415489","volume":"23","author":"X Guo","year":"2022","unstructured":"Guo X, Yin X, Liu Z et al (2022) Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci 23(24):15489","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4600_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/apt.16066","volume":"52","author":"Y Jung","year":"2020","unstructured":"Jung Y, Lee MK, Puri P et al (2020) Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 52(10):1603\u20131614","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"4600_CR16","first-page":"805","volume":"25","author":"Li Junxiang","year":"2017","unstructured":"Junxiang Li, Yi C, Yunliang W (2017) Consensus on diagnosis and treatment of nonalcoholic fatty liver disease with integrated traditional Chinese and Western medicine (2017) [J]. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 25(11):805\u2013811","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine on Digestion"},{"issue":"7","key":"4600_CR17","first-page":"33","volume":"54","author":"WT Lu","year":"2022","unstructured":"Lu WT, Liu LN, Chen QL et al (2022) Clinical study of \u201cJiu Wei Qing Zhi Gao\u201d in treating 68 cases of NAFLD with liver-qi and spleen-deficiency. Jiangsu J of TCM 54(7):33\u201336","journal-title":"Jiangsu J of TCM"},{"key":"4600_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2016.27","volume":"6","author":"DWL Ma","year":"2016","unstructured":"Ma DWL, Arendt BM, Hillyer LM et al (2016) Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects. Nutr Diabetes 6:e220","journal-title":"Nutr Diabetes"},{"issue":"12","key":"4600_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","volume":"18","author":"M Masoodi","year":"2021","unstructured":"Masoodi M, Gastaldelli A, Hy\u00f6tyl\u00e4inen T et al (2021) Lipidomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 18(12):835\u2013856","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"4600_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100477","volume":"4","author":"AJ McGlinchey","year":"2022","unstructured":"McGlinchey AJ, Govaere O, Geng D et al (2022) Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports 4(5):100477","journal-title":"JHEP Reports"},{"issue":"8","key":"4600_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD et al (2024) Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab 35(8):697\u2013707","journal-title":"Trends Endocrinol Metab"},{"key":"4600_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/bs.acr.2018.05.002","volume":"140","author":"M Nikolova-Karakashian","year":"2018","unstructured":"Nikolova-Karakashian M (2018) Sphingolipids at the crossroads of NAFLD and senescence. Adv Cancer Res 140:155\u2013190","journal-title":"Adv Cancer Res"},{"issue":"3","key":"4600_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2021.04.013","volume":"75","author":"GJ Ooi","year":"2021","unstructured":"Ooi GJ, Meikle PJ, Huynh K et al (2021) Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol 75(3):524\u2013535","journal-title":"J Hepatol"},{"key":"4600_CR24","doi-asserted-by":"publisher","first-page":"1027628","DOI":"10.3389\/fphar.2022.1027628","volume":"13","author":"Y Pan","year":"2022","unstructured":"Pan Y, Guo J, Hu N, Xun Y et al (2022) Distinct common signatures of gut microbiota associated with damp-heat syndrome in patients with different chronic liver diseases. Front Pharmacol 13:1027628","journal-title":"Front Pharmacol"},{"issue":"6","key":"4600_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul B, Lewinska M, Andersen JB (2022) Lipid alterations in chronic liver disease and liver cancer. JHEP Rep 4(6):100479","journal-title":"JHEP Rep"},{"issue":"S","key":"4600_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154320","volume":"111","author":"N Perakakis","year":"2020","unstructured":"Perakakis N, Stefanakis K, Mantzoros CS (2020a) The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 111(S):154320","journal-title":"Metabolism"},{"issue":"S","key":"4600_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154320","volume":"111","author":"N Perakakis","year":"2020","unstructured":"Perakakis N, Stefanakis K, Mantzoros CS (2020b) The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 111(S):154320","journal-title":"Metabolism"},{"key":"4600_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.934847","volume":"13","author":"JJ Pyo","year":"2022","unstructured":"Pyo JJ, Choi Y (2022) Key hepatic signatures of human and mouse nonalcoholic steatohepatitis: a transcriptome-proteome data meta-analysis. Front Endocrinol (Lausanne) 13:934847","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4600_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY et al (2023) Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 8(1):20\u201330","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4600_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biochi.2018.07.021","volume":"159","author":"M R\u00e9gnier","year":"2019","unstructured":"R\u00e9gnier M, Polizzi A, Guillou H et al (2019) Sphingolipid metabolism in non-alcoholic fatty liver diseases. Biochimie 159:9\u201322","journal-title":"Biochimie"},{"issue":"13","key":"4600_CR31","doi-asserted-by":"publisher","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","volume":"16","author":"L Rong","year":"2023","unstructured":"Rong L, Zou J, Ran W et al (2023) Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne) 16(13):1087260","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4600_CR32","doi-asserted-by":"crossref","unstructured":"Sana, Raza,Sangam, Rajak,Aditya, Upadhyay et al. Current treatment paradigms and emerging therapies for NAFLD\/NASH.[J] .Front Biosci (Landmark Ed), 2020, 26(2):206\u2013237.","DOI":"10.2741\/4892"},{"key":"4600_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-981-19-0394-6_8","volume":"1372","author":"L Sasset","year":"2022","unstructured":"Sasset L, Di Lorenzo A (2022) Sphingolipid metabolism and signaling in endothelial cell functions. Adv Exp Med Biol 1372:87\u2013117","journal-title":"Adv Exp Med Biol"},{"key":"4600_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115477","volume":"296","author":"H Shi","year":"2022","unstructured":"Shi H, Qiao F, Huang K et al (2022) Exploring therapeutic mechanisms of San-huang-tang in nonalcoholic fatty liver disease through network pharmacology and experimental validation. J Ethnopharmacol 296:115477","journal-title":"J Ethnopharmacol"},{"key":"4600_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1050049","volume":"14","author":"Y Tan","year":"2023","unstructured":"Tan Y, He Q, Chan KHK (2023) Identification of shared genetic architecture between non-alcoholic fatty liver disease and type 2 diabetes: a genome-wide analysis. Front Endocrinol (Lausanne) 14:1050049","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4600_CR36","first-page":"3920196","volume":"31","author":"DM Tanase","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF et al (2020) The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res 31:3920196","journal-title":"J Diabetes Res"},{"issue":"4","key":"4600_CR37","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/HEP.0000000000000375","volume":"79","author":"Y Tian","year":"2024","unstructured":"Tian Y, Jellinek MJ, Mehta K et al (2024) Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis. Hepatology 79(4):882\u2013897","journal-title":"Hepatology"},{"key":"4600_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100104","volume":"62","author":"O Vvedenskaya","year":"2021","unstructured":"Vvedenskaya O, Rose TD, Knittelfelder O et al (2021) Nonalcoholic fatty liver disease stratification by liver lipidomics. J Lipid Res 62:100104","journal-title":"J Lipid Res"},{"key":"4600_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jad.2024.01.053","volume":"349","author":"Y Wang","year":"2024","unstructured":"Wang Y, Cai X, Ma Y et al (2024) Lipidomics on depression: a comparison of clinical and animal research. J Affect Disord 349:559\u2013568","journal-title":"J Affect Disord"},{"key":"4600_CR40","unstructured":"Lu Weiting, Shi Huilian, Liu Lina, et al. Observation of the therapeutic effect of Jiuwei Qingzhi Gao in improving liver inflammation in a mouse model of non-alcoholic steatohepatitis. Liaoning Journal of Traditional Chinese Medicine, 2023, 50(03): 184\u2013187 + 223."},{"issue":"11","key":"4600_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113730","volume":"12","author":"HC Wu","year":"2023","unstructured":"Wu HC, Hsieh YR, Wang W et al (2023) Potential hepatic lipid markers associated with nonalcoholic steatohepatitis and fibrosis in morbid obesity patients. J Clin Med 12(11):3730","journal-title":"J Clin Med"},{"key":"4600_CR42","first-page":"8917993","volume":"31","author":"YW Zhu","year":"2021","unstructured":"Zhu YW, Li D, Ye TJ et al (2021a) The study of Yin-Chen-Hao-Tang preventing and treating alcoholic fatty liver disease through PPAR signaling pathway based on network pharmacology and RNA-Seq transcriptomics. Evid Based Complement Alternat Med 31:8917993","journal-title":"Evid Based Complement Alternat Med"},{"key":"4600_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.635818","volume":"9","author":"K Zhu","year":"2021","unstructured":"Zhu K, Guo Y, Zhao C et al (2021b) Etiology exploration of non-alcoholic fatty liver disease from traditional Chinese medicine constitution perspective: a cross-sectional study. Front Public Health 9:635818","journal-title":"Front Public Health"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04600-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:02:56Z","timestamp":1776225776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4600"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04600-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial has been registered in China Clinical Trial Registration Center (CHIC TR 2300079299) (\n                      \n                      index. aspx). At the time of submitting this Manuscript, the experimental state was in the recruitment stage. The recruitment is expected to be completed in December 2024. The research involving human participants in this project was reviewed and approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Traditional Chinese Medicine. The approval number is 2023NL-093\u201301. Patients\/participants provided written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial status and ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}